Corrigendum to “Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study” (Gynecologic Oncology (2018) 151(1) (18–23), (S0090825818310850) (10.1016/j.ygyno.2018.07.021))

Alexander B. Olawaiye, James J. Java, Thomas C. Krivak, Michael Friedlander, David G. Mutch, Gretchen Glaser, Melissa Geller, David M. O'Malley, Robert M. Wenham, Roger B. Lee, Diane C. Bodurka, Thomas J. Herzog, Michael A. Bookman

Research output: Contribution to journalComment/debate

Abstract

The authors regret that there was some conflict of interest information missing from their original article. The conflict of interest statement for Dr. Robert Wenham has now been updated in the online version and can be found below: Dr. Wenham reports being a research fund recipient, consultant, advisor, steering committee or DSMB member, or speaker for Tesaro, Clovis, Genentech, Merck, Ovation Diagnostics, Janseen, Mersana, and Tapimmune. The authors would like to apologise for any inconvenience caused.

Original languageEnglish (US)
Number of pages1
JournalGynecologic oncology
Volume152
Issue number1
DOIs
StatePublished - Jan 2019

PubMed: MeSH publication types

  • Journal Article
  • Published Erratum

Fingerprint Dive into the research topics of 'Corrigendum to “Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study” (Gynecologic Oncology (2018) 151(1) (18–23), (S0090825818310850) (10.1016/j.ygyno.2018.07.021))'. Together they form a unique fingerprint.

  • Cite this